NO2892889T3 - - Google Patents
Info
- Publication number
- NO2892889T3 NO2892889T3 NO13760106A NO13760106A NO2892889T3 NO 2892889 T3 NO2892889 T3 NO 2892889T3 NO 13760106 A NO13760106 A NO 13760106A NO 13760106 A NO13760106 A NO 13760106A NO 2892889 T3 NO2892889 T3 NO 2892889T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1216017.2A GB201216017D0 (en) | 2012-09-07 | 2012-09-07 | Inhibitor compounds |
PCT/GB2013/052360 WO2014037750A1 (en) | 2012-09-07 | 2013-09-09 | Inhibitor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2892889T3 true NO2892889T3 (no) | 2018-03-17 |
Family
ID=47137117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO13760106A NO2892889T3 (no) | 2012-09-07 | 2013-09-09 |
Country Status (22)
Country | Link |
---|---|
US (6) | US9409907B2 (no) |
EP (2) | EP2892889B1 (no) |
JP (2) | JP6216791B2 (no) |
CN (1) | CN104837829B (no) |
AU (2) | AU2013311434B2 (no) |
BR (1) | BR112015004489B1 (no) |
CA (1) | CA2884006C (no) |
CY (1) | CY1119714T1 (no) |
DK (2) | DK3293183T3 (no) |
ES (2) | ES2742442T3 (no) |
GB (1) | GB201216017D0 (no) |
HK (1) | HK1211921A1 (no) |
HR (1) | HRP20171835T1 (no) |
HU (1) | HUE036259T2 (no) |
LT (1) | LT2892889T (no) |
NO (1) | NO2892889T3 (no) |
PL (1) | PL2892889T3 (no) |
PT (1) | PT2892889T (no) |
RS (1) | RS56750B1 (no) |
RU (1) | RU2673079C2 (no) |
SI (1) | SI2892889T1 (no) |
WO (1) | WO2014037750A1 (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
EP2268647B1 (en) | 2008-03-21 | 2017-01-25 | The General Hospital Corporation | Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
JP6559132B2 (ja) | 2013-08-23 | 2019-08-14 | ニューファーマ, インコーポレイテッド | ある特定の化学的実体、組成物および方法 |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
US10947201B2 (en) | 2015-02-17 | 2021-03-16 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
ES2966392T3 (es) | 2015-04-17 | 2024-04-22 | Crossfire Oncology Holding B V | Biomarcadores pronósticos para quimioterapia inhibidora de TTK |
CN107614499B (zh) * | 2015-05-29 | 2020-09-18 | 帝人制药株式会社 | 吡啶并[3,4-d]嘧啶衍生物及其药学上可允许的盐 |
EP3354653B1 (en) | 2015-07-21 | 2019-09-04 | Guangzhou Maxinovel Pharmaceuticals Co. Ltd. | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof |
GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
EP4006035B1 (en) | 2016-08-15 | 2023-11-22 | Neupharma, Inc. | Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer |
AU2017364805B2 (en) | 2016-11-28 | 2021-12-16 | Teijin Pharma Limited | Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof |
MY196497A (en) * | 2016-11-28 | 2023-04-17 | Teijin Pharma Ltd | Pyrido[3, 4-D]Pyrimidine Derivative And Pharmaceutically Acceptable Salt Thereof |
GB201709840D0 (en) * | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
US20200171032A1 (en) * | 2017-06-20 | 2020-06-04 | The Institute Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
EP3701304B1 (en) | 2017-10-26 | 2022-05-04 | CommScope Connectivity Belgium BVBA | Telecommunications system |
GB201809460D0 (en) | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
GB201809458D0 (en) | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
BR112023009531A2 (pt) | 2020-11-18 | 2023-10-03 | Deciphera Pharmaceuticals Llc | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2697710A (en) | 1953-01-02 | 1954-12-21 | Burroughs Wellcome Co | Pyrido (2,3-d) pyrimidines and method of preparing same |
US3021332A (en) | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
DE69515898T2 (de) | 1994-11-14 | 2000-08-17 | Warner Lambert Co | 6-ARYL-PYRIDO[2,3-d]PYRIMIDINE UND -NAPHTHYRIDINE ZUR HEMMUNG DER DURCH PROTEIN-TYROSIN-KINASE HERVORGERUFENEN ZELLVERMEHRUNG |
US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
AR030044A1 (es) | 2000-01-25 | 2003-08-13 | Warner Lambert Co | Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas |
AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
AU2002324450A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidines and uses thereof |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2002353147A1 (en) | 2001-12-13 | 2003-06-30 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
JP4187657B2 (ja) | 2002-03-07 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | p38キナーゼインヒビターとしての二環式ピリジン及びピリミジン |
CA2492112A1 (en) * | 2002-08-06 | 2004-02-19 | F. Hoffmann-La Roche Ag | 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
CA2505427C (en) | 2002-11-12 | 2012-04-03 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
DK1899322T3 (da) | 2005-06-28 | 2009-12-14 | Sanofi Aventis | Isoquinolin-derivater som hæmmere af Rho-kinase |
RU2441869C2 (ru) * | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
JP2010514693A (ja) * | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Pdk1阻害のためのキナゾリン |
WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
WO2009084695A1 (ja) * | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | 2-アミノキナゾリン誘導体 |
GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
CA2791738C (en) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Aryl imidazolyl compounds for the treatment of cancer |
GB201011182D0 (en) | 2010-07-02 | 2010-08-18 | Wireless Fibre Systems Ltd | Riser wireless communications system |
EP2598508B1 (en) * | 2010-07-30 | 2015-04-22 | Nerviano Medical Sciences S.r.l. | Isoxazolo-quinazolines as modulators of protein kinase activity |
ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
EP2630136A1 (en) | 2010-10-21 | 2013-08-28 | Universität des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
US8623889B2 (en) | 2010-12-17 | 2014-01-07 | Genentech, Inc. | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
US8883793B2 (en) | 2010-12-29 | 2014-11-11 | Development Center For Biotechnology | Tubulin inhibitors and methods of using the same |
CN103339134B (zh) * | 2011-01-26 | 2015-12-23 | 内尔维阿诺医学科学有限公司 | 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用 |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
US9745191B2 (en) | 2011-04-11 | 2017-08-29 | Saudi Arabian Oil Company | Auto thermal reforming (ATR) catalytic structures |
PT2739153T (pt) | 2011-07-29 | 2018-11-28 | Univ Colorado Regents | Tratamento de cancro da mama |
CA2850394C (en) | 2011-10-12 | 2019-05-21 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
WO2014134169A1 (en) | 2013-02-26 | 2014-09-04 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
CN105916501A (zh) | 2013-12-06 | 2016-08-31 | 豪夫迈·罗氏有限公司 | 用于治疗局部晚期或转移性***受体阳性乳腺癌的***受体调节剂 |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
AU2015230677A1 (en) | 2014-03-11 | 2016-10-27 | The Council Of The Queensland Institute Of Medical Research | Determining cancer agressiveness, prognosis and responsiveness to treatment |
AU2015289929A1 (en) | 2014-07-14 | 2017-03-02 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
WO2016073771A2 (en) | 2014-11-06 | 2016-05-12 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors |
GB201522532D0 (en) | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
US20200171032A1 (en) | 2017-06-20 | 2020-06-04 | The Institute Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
-
2012
- 2012-09-07 GB GBGB1216017.2A patent/GB201216017D0/en not_active Ceased
-
2013
- 2013-09-09 RS RS20171314A patent/RS56750B1/sr unknown
- 2013-09-09 HU HUE13760106A patent/HUE036259T2/hu unknown
- 2013-09-09 AU AU2013311434A patent/AU2013311434B2/en active Active
- 2013-09-09 BR BR112015004489-1A patent/BR112015004489B1/pt active IP Right Grant
- 2013-09-09 RU RU2015112580A patent/RU2673079C2/ru active
- 2013-09-09 DK DK17192253.7T patent/DK3293183T3/da active
- 2013-09-09 ES ES17192253T patent/ES2742442T3/es active Active
- 2013-09-09 EP EP13760106.8A patent/EP2892889B1/en active Active
- 2013-09-09 ES ES13760106.8T patent/ES2655194T3/es active Active
- 2013-09-09 PL PL13760106T patent/PL2892889T3/pl unknown
- 2013-09-09 US US14/426,549 patent/US9409907B2/en active Active
- 2013-09-09 WO PCT/GB2013/052360 patent/WO2014037750A1/en active Application Filing
- 2013-09-09 PT PT137601068T patent/PT2892889T/pt unknown
- 2013-09-09 LT LTEP13760106.8T patent/LT2892889T/lt unknown
- 2013-09-09 CN CN201380057967.7A patent/CN104837829B/zh active Active
- 2013-09-09 CA CA2884006A patent/CA2884006C/en active Active
- 2013-09-09 DK DK13760106.8T patent/DK2892889T3/en active
- 2013-09-09 JP JP2015530495A patent/JP6216791B2/ja active Active
- 2013-09-09 SI SI201330829T patent/SI2892889T1/sl unknown
- 2013-09-09 NO NO13760106A patent/NO2892889T3/no unknown
- 2013-09-09 EP EP17192253.7A patent/EP3293183B1/en active Active
-
2015
- 2015-12-23 HK HK15112642.0A patent/HK1211921A1/xx unknown
-
2016
- 2016-04-06 US US15/091,980 patent/US9834552B2/en active Active
- 2016-04-06 US US15/091,887 patent/US9890157B2/en active Active
-
2017
- 2017-09-22 JP JP2017182377A patent/JP6496376B2/ja active Active
- 2017-11-24 HR HRP20171835TT patent/HRP20171835T1/hr unknown
- 2017-11-27 AU AU2017268488A patent/AU2017268488B2/en active Active
- 2017-12-29 CY CY20171101358T patent/CY1119714T1/el unknown
-
2018
- 2018-01-08 US US15/864,499 patent/US10479788B2/en active Active
-
2019
- 2019-10-10 US US16/598,717 patent/US11046688B2/en active Active
-
2021
- 2021-05-13 US US17/319,231 patent/US11897877B2/en active Active